Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine
Nasamon Wanlapakorn, View ORCID ProfileRitthideach Yorsaeng, Harit Phowatthanasathian, View ORCID ProfileNungruthai Suntronwong, View ORCID ProfileSitthichai Kanokudom, Natthinee Sudhinaraset, Yong Poovorawan
doi: https://doi.org/10.1101/2021.11.20.21266644
Nasamon Wanlapakorn
1Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Ritthideach Yorsaeng
1Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Harit Phowatthanasathian
1Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Nungruthai Suntronwong
1Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Sitthichai Kanokudom
1Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Natthinee Sudhinaraset
1Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Yong Poovorawan
1Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
2FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok 10330, Thailand
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
All data produced in the present work are contained in the manuscript
Posted November 21, 2021.
Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine
Nasamon Wanlapakorn, Ritthideach Yorsaeng, Harit Phowatthanasathian, Nungruthai Suntronwong, Sitthichai Kanokudom, Natthinee Sudhinaraset, Yong Poovorawan
medRxiv 2021.11.20.21266644; doi: https://doi.org/10.1101/2021.11.20.21266644
Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine
Nasamon Wanlapakorn, Ritthideach Yorsaeng, Harit Phowatthanasathian, Nungruthai Suntronwong, Sitthichai Kanokudom, Natthinee Sudhinaraset, Yong Poovorawan
medRxiv 2021.11.20.21266644; doi: https://doi.org/10.1101/2021.11.20.21266644
Subject Area
Subject Areas
- Addiction Medicine (408)
- Allergy and Immunology (719)
- Anesthesia (214)
- Cardiovascular Medicine (3035)
- Dermatology (258)
- Emergency Medicine (456)
- Epidemiology (12959)
- Forensic Medicine (12)
- Gastroenterology (848)
- Genetic and Genomic Medicine (4770)
- Geriatric Medicine (440)
- Health Economics (747)
- Health Informatics (3026)
- Health Policy (1095)
- Hematology (405)
- HIV/AIDS (951)
- Medical Education (450)
- Medical Ethics (119)
- Nephrology (490)
- Neurology (4544)
- Nursing (242)
- Nutrition (671)
- Oncology (2361)
- Ophthalmology (666)
- Orthopedics (264)
- Otolaryngology (332)
- Pain Medicine (296)
- Palliative Medicine (85)
- Pathology (512)
- Pediatrics (1229)
- Primary Care Research (515)
- Public and Global Health (7132)
- Radiology and Imaging (1586)
- Respiratory Medicine (940)
- Rheumatology (456)
- Sports Medicine (396)
- Surgery (503)
- Toxicology (63)
- Transplantation (218)
- Urology (187)